Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Glioma | Research

HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas

Authors: Huaxin Zhu, Jiacong Tan, Xinyi Pan, Hengyang Ouyang, Zhixiong Zhang, Meihua Li, Yeyu Zhao

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Gliomas are the most frequent type of central nervous system tumor, accounting for more than 70% of all malignant CNS tumors. Recent research suggests that the hyaluronan-mediated motility receptor (HMMR) could be a novel potential tumor prognostic marker. Furthermore, mounting data has highlighted the important role of ceRNA regulatory networks in a variety of human malignancies. The complexity and behavioural characteristics of HMMR and the ceRNA network in gliomas, on the other hand, remained unknown.

Methods

Transcriptomic expression data were collected from TCGA, GTEx, GEO, and CGGA database.The relationship between clinical variables and HMMR was analyzed with the univariate and multivariate Cox regression. Kaplan–Meier method was used to assess OS. TCGA data are analyzed and processed, and the correlation results obtained were used to perform GO, GSEA, and ssGSEA. Potentially interacting miRNAs and lncRNAs were predicted by miRWalk and StarBase.

Results

HMMR was substantially expressed in gliomas tissues compared to normal tissues. Multivariate analysis revealed that high HMMR expression was an independent predictive predictor of OS in TCGA and CGGA. Functional enrichment analysis found that HMMR expression was associated with nuclear division and cell cycle. Base on ssGSEA analysis, The levels of HMMR expression in various types of immune cells differed significantly. Bioinformatics investigation revealed the HEELPAR-hsa-let-7i-5p-RRM2 ceRNA network, which was linked to gliomas prognosis. And through multiple analysis, the good predictive performance of HELLPAR/RRM2 axis for gliomas patients was confirmed.

Conclusion

This study provides multi-layered and multifaceted evidence for the importance of HMMR and establishes a HMMR-related ceRNA (HEELPAR-hsa-let-7i-5p-RRM2) overexpressed network related to the prognosis of gliomas.

Available only for authorised users

Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review J Clin Neurosci. 2018;54:7–13. https://doi.org/10.1016/j.jocn.2018.05.002.CrossRef

Liu CA, Chang CY, Hsueh KW, Su HL, Chiou TW, Lin SZ, et al. Migration/invasion of malignant gliomas and implications for therapeutic treatment. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19041115

Desland FA, Hormigo A. The cns and the brain tumor microenvironment: implications for glioblastoma immunotherapy. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21197358

Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2-8. https://doi.org/10.1188/16.CJON.S1.2-8.CrossRef

Lee E, Yong RL, Paddison P, Zhu J. Comparison of glioblastoma (gbm) molecular classification methods. Semin Cancer Biol. 2018;53:201–11. https://doi.org/10.1016/j.semcancer.2018.07.006.CrossRef

Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment. Recent literature review Curr Med Chem. 2017;24:3002–9. https://doi.org/10.2174/0929867324666170516123206.CrossRef

Richardson TE, Patel S, Serrano J, Sathe AA, Daoud EV, Oliver D, et al. Genome-wide analysis of glioblastoma patients with unexpectedly long survival. J Neuropathol Exp Neurol. 2019;78:501–7. https://doi.org/10.1093/jnen/nlz025.CrossRef

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22:1478–90. https://doi.org/10.1634/theoncologist.2017-0242.CrossRef

Quinones A, Le A. The multifaceted metabolism of glioblastoma. Adv Exp Med Biol. 2018;1063:59–72. https://doi.org/10.1007/978-3-319-77736-8_4.CrossRef

10.

Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14:284–97. https://doi.org/10.1007/s13311-017-0519-x.CrossRef

11.

Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, et al. Clinical insights gained by refining the 2016 who classification of diffuse gliomas with: egfr amplification, tert mutations, pten deletion and mgmt methylation. BMC Cancer. 2019;19:968. https://doi.org/10.1186/s12885-019-6177-0.CrossRef

12.

Izquierdo C, Joubert B, Ducray F. Anaplastic gliomas in adults: an update. Curr Opin Oncol. 2017;29:434–42. https://doi.org/10.1097/CCO.0000000000000409.CrossRef

13.

Hardwick C, Hoare K, Owens R, Hohn HP, Hook M, Moore D, et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol. 1992;117:1343–50. https://doi.org/10.1083/jcb.117.6.1343.CrossRef

14.

Schwertfeger KL, Cowman MK, Telmer PG, Turley EA, McCarthy JB. Hyaluronan, inflammation, and breast cancer progression. Front Immunol. 2015;6:236. https://doi.org/10.3389/fimmu.2015.00236.CrossRef

15.

Kang HG, Kim WJ, Kang HG, Chun KH, Kim SJ. Galectin-3 interacts with c/ebpbeta and upregulates hyaluronan-mediated motility receptor expression in gastric cancer. Mol Cancer Res. 2020;18:403–13. https://doi.org/10.1158/1541-7786.MCR-19-0811.CrossRef

16.

Yang D, Ma Y, Zhao P, Ma J, He C. Hmmr is a downstream target of foxm1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells. Exp Cell Res. 2021;408:112860. https://doi.org/10.1016/j.yexcr.2021.112860.CrossRef

17.

Sun Y, Li Z, Song K. Ar-mtor-srf axis regulates hmmr expression in human prostate cancer cells. Biomol Ther (Seoul). 2021;29:667–77. https://doi.org/10.4062/biomolther.2021.040.CrossRef

18.

Mohan P, Castellsague J, Jiang J, Allen K, Chen H, Nemirovsky O, et al. Genomic imbalance of hmmr/rhamm regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. Oncotarget. 2013;4:80–93. https://doi.org/10.18632/oncotarget.793.CrossRef

19.

Yang J, Du X. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surg Oncol. 2013;22:e53–7. https://doi.org/10.1016/j.suronc.2013.06.003.CrossRef

20.

Tilghman J, Wu H, Sang Y, Shi X, Guerrero-Cazares H, Quinones-Hinojosa A, et al. Hmmr maintains the stemness and tumorigenicity of glioblastoma stem-like cells. Cancer Res. 2014;74:3168–79. https://doi.org/10.1158/0008-5472.CAN-13-2103.CrossRef

21.

Wienholds E, Plasterk RH. Microrna function in animal development. Febs Lett. 2005;579:5911–22. https://doi.org/10.1016/j.febslet.2005.07.070.CrossRef

22.

Wilusz JE. Long noncoding rnas: re-writing dogmas of rna processing and stability. Biochim Biophys Acta. 2016;1859:128–38. https://doi.org/10.1016/j.bbagrm.2015.06.003.CrossRef

23.

Tong Y, Yang L, Yu C, Zhu W, Zhou X, Xiong Y, et al. Tumor-secreted exosomal lncrna pou3f3 promotes cisplatin resistance in escc by inducing fibroblast differentiation into cafs. Mol Ther Oncolytics. 2020;18:1–13. https://doi.org/10.1016/j.omto.2020.05.014.CrossRef

24.

Zhang Y, Huang YX, Wang DL, Yang B, Yan HY, Lin LH, et al. Lncrna dscam-as1 interacts with ybx1 to promote cancer progression by forming a positive feedback loop that activates foxa1 transcription network. Theranostics. 2020;10:10823–37. https://doi.org/10.7150/thno.47830.CrossRef

25.

Zhu J, Zhang Y, Chen X, Bian Y, Li J, Wang K. The emerging roles of linc00665 in human cancers. Front Cell Dev Biol. 2022;10:839177. https://doi.org/10.3389/fcell.2022.839177.CrossRef

26.

Teng F, Zhang JX, Chang QM, Wu XB, Tang WG, Wang JF, et al. Lncrna mylk-as1 facilitates tumor progression and angiogenesis by targeting mir-424-5p/e2f7 axis and activating vegfr-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:235. https://doi.org/10.1186/s13046-020-01739-z.CrossRef

27.

Zhou R, Sun H, Zheng S, Zhang J, Zeng D, Wu J, et al. A stroma-related lncrna panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer. J Cell Mol Med. 2020;24:3229–41. https://doi.org/10.1111/jcmm.14999.CrossRef

28.

Sheng J, He X, Yu W, Chen Y, Long Y, Wang K, et al. P53-targeted lncrna st7-as1 acts as a tumour suppressor by interacting with ptbp1 to suppress the wnt/beta-catenin signalling pathway in glioma. Cancer Lett. 2021;503:54–68. https://doi.org/10.1016/j.canlet.2020.12.039.CrossRef

29.

Tang G, Luo L, Zhang J, Zhai D, Huang D, Yin J, et al. Lncrna linc01057 promotes mesenchymal differentiation by activating nf-kappab signaling in glioblastoma. Cancer Lett. 2021;498:152–64. https://doi.org/10.1016/j.canlet.2020.10.047.CrossRef

30.

Mu M, Niu W, Zhang X, Hu S, Niu C. Lncrna bcyrn1 inhibits glioma tumorigenesis by competitively binding with mir-619-5p to regulate cuedc2 expression and the pten/akt/p21 pathway. Oncogene. 2020;39:6879–92. https://doi.org/10.1038/s41388-020-01466-x.CrossRef

31.

Fu C, Li D, Zhang X, Liu N, Chi G, Jin X. Lncrna pvt1 facilitates tumorigenesis and progression of glioma via regulation of mir-128-3p/grem1 axis and bmp signaling pathway. Neurotherapeutics. 2018;15:1139–57. https://doi.org/10.1007/s13311-018-0649-9.CrossRef

32.

Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. https://doi.org/10.1016/s0092-8674(04)00045-5.CrossRef

33.

Sharma U, Conine CC, Shea JM, Boskovic A, Derr AG, Bing XY, et al. Biogenesis and function of trna fragments during sperm maturation and fertilization in mammals. Science. 2016;351:391–6. https://doi.org/10.1126/science.aad6780.CrossRef

34.

Zhang N, Hu G, Myers TG, Williamson PR. Protocols for the analysis of microrna expression, biogenesis, and function in immune cells. Curr Protoc Immunol. 2019;126:e78. https://doi.org/10.1002/cpim.78.CrossRef

35.

Zhang PF, Pei X, Li KS, Jin LN, Wang F, Wu J, et al. Circular rna circfgfr1 promotes progression and anti-pd-1 resistance by sponging mir-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019;18:179. https://doi.org/10.1186/s12943-019-1111-2.CrossRef

36.

Shi Y, Zhang DD, Liu JB, Yang XL, Xin R, Jia CY, et al. Comprehensive analysis to identify dleu2l/taok1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2021;23:702–18. https://doi.org/10.1016/j.omtn.2020.12.016.CrossRef

37.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A cerna hypothesis: the rosetta stone of a hidden rna language? Cell. 2011;146:353-8. https://doi.org/10.1016/j.cell.2011.07.014

38.

Chan JJ, Tay Y. Noncoding rna:rna regulatory networks in cancer. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19051310

39.

Mu Y, Tang Q, Feng H, Zhu L, Wang Y. Lncrna ktn1as1 promotes glioma cell proliferation and invasion by negatively regulating mir5053p. Oncol Rep. 2020;44:2645–55. https://doi.org/10.3892/or.2020.7821.CrossRef

40.

Li Y, Wang X, Zhao Z, Shang J, Li G, Zhang R. Lncrna neat1 promotes glioma cancer progression via regulation of mir-98-5p/bzw1. Biosci Rep. https://doi.org/10.1042/BSR20200767

41.

Xin J, Zhao YH, Zhang XY, Tian LQ. Lncrna nfia-as2 promotes glioma progression through modulating the mir-655-3p/zfx axis. Hum Cell. 2020;33:1273–80. https://doi.org/10.1007/s13577-020-00408-9.CrossRef

42.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for rna-seq data with deseq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.CrossRef

43.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. https://doi.org/10.1093/nar/gkv007.CrossRef

44.

Yu G, Wang LG, Han Y, He QY. Clusterprofiler: an r package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7. https://doi.org/10.1089/omi.2011.0118.CrossRef

45.

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. Kegg: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49:D545–51. https://doi.org/10.1093/nar/gkaa970.CrossRef

46.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947–51. https://doi.org/10.1002/pro.3715.CrossRef

47.

Hanzelmann S, Castelo R, Guinney J. Gsva: gene set variation analysis for microarray and rna-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7.CrossRef

48.

Li JH, Liu S, Zhou H, Qu LH, Yang JH. Starbase v2.0: decoding mirna-cerna, mirna-ncrna and protein-rna interaction networks from large-scale clip-seq data. Nucleic Acids Res. 2014;42:92–7. https://doi.org/10.1093/nar/gkt1248.CrossRef

49.

Guo X, Wang T, Huang G, Li R, Da CC, Li H, et al. Rediscovering potential molecular targets for glioma therapy through the analysis of the cell of origin, microenvironment and metabolism. Curr Cancer Drug Targets. 2021;21:558–74. https://doi.org/10.2174/1568009621666210504091722.CrossRef

50.

Muller BJ, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020;122:295–305. https://doi.org/10.1038/s41416-019-0603-6.CrossRef

51.

Ross JL, Velazquez VJ, Plant A, MacDonald TJ, Becher OJ, Hambardzumyan D. Tumour immune landscape of paediatric high-grade gliomas. Brain. 2021;144:2594–609. https://doi.org/10.1093/brain/awab155.CrossRef

52.

Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: impact of the world health organization 2021 update. Brain Pathol. 2022:e13062. https://doi.org/10.1111/bpa.13062

53.

Pienkowski T, Kowalczyk T, Garcia-Romero N, Ayuso-Sacido A, Ciborowski M. Proteomics and metabolomics approach in adult and pediatric glioma diagnostics. Biochim Biophys Acta Rev Cancer. 2022:88721. https://doi.org/10.1016/j.bbcan.2022.188721

54.

Wang QW, Zhao Z, Bao ZS, Jiang T, Zhu YJ. Comprehensive analysis of multi-omics data of recurrent gliomas identifies a recurrence-related signature as a novel prognostic marker. Am J Cancer Res. 2021;11:1226–46.

55.

Su W, Liao M, Tan H, Chen Y, Zhao R, Jin W, et al. Identification of autophagic target rab13 with small-molecule inhibitor in low-grade glioma via integrated multi-omics approaches coupled with virtual screening of traditional chinese medicine databases. Cell Prolif. 2021;54:e13135. https://doi.org/10.1111/cpr.13135.CrossRef

56.

Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein rhamm/ihabp in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol. 2001;195:191–6. https://doi.org/10.1002/path.941.CrossRef

57.

Zlobec I, Baker K, Terracciano LM, Lugli A. Rhamm, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res. 2008;14:3798–806. https://doi.org/10.1158/1078-0432.CCR-07-5103.CrossRef

58.

Li H, Guo L, Li JW, Liu N, Qi R, Liu J. Expression of hyaluronan receptors cd44 and rhamm in stomach cancers: relevance with tumor progression. Int J Oncol. 2000;17:927–32.

59.

Rein DT, Roehrig K, Schondorf T, Lazar A, Fleisch M, Niederacher D, et al. Expression of the hyaluronan receptor rhamm in endometrial carcinomas suggests a role in tumour progression and metastasis. J Cancer Res Clin Oncol. 2003;129:161–4. https://doi.org/10.1007/s00432-003-0415-0.CrossRef

60.

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, et al. Rhamm (cd168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009;11:956–63. https://doi.org/10.1593/neo.09694.CrossRef

61.

Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, et al. Rhamm expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004;104:1151–8. https://doi.org/10.1182/blood-2003-11-4079.CrossRef

62.

Ping Y, Zhou Y, Hu J, Pang L, Xu C, Xiao Y. Dissecting the functional mechanisms of somatic copy-number alterations based on dysregulated cerna networks across cancers. Mol Ther Nucleic Acids. 2020;21:464–79. https://doi.org/10.1016/j.omtn.2020.06.012.CrossRef

63.

Zhao W, Geng D, Li S, Chen Z, Sun M. Lncrna hotair influences cell growth, migration, invasion, and apoptosis via the mir-20a-5p/hmga2 axis in breast cancer. Cancer Med. 2018;7:842–55. https://doi.org/10.1002/cam4.1353.CrossRef

64.

Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, et al. A novel lncrna uc.134 represses hepatocellular carcinoma progression by inhibiting cul4a-mediated ubiquitination of lats1. J Hematol Oncol. 2017;10:91. https://doi.org/10.1186/s13045-017-0449-4.CrossRef

65.

Tang YP, Yin YX, Xie MZ, Liang XQ, Li JL, Li KZ, et al. Systematic analysis of the clinical significance of hyaluronan-mediated motility receptor in colorectal cancer. Front Mol Biosci. 2021;8:733271. https://doi.org/10.3389/fmolb.2021.733271.CrossRef

66.

Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, et al. High-resolution dna copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008;14:1015–24. https://doi.org/10.1158/1078-0432.CCR-07-1305.CrossRef

67.

Hamon P, Gerbe DTM, Classe M, Signolle N, Liu W, Bawa O, et al. Tgfbeta receptor inhibition unleashes interferon-beta production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer. 2022;10. https://doi.org/10.1136/jitc-2021-003519

68.

Esteban-Fabro R, Willoughby CE, Pique-Gili M, Montironi C, Abril-Fornaguera J, Peix J, et al. Cabozantinib enhances anti-pd1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin Cancer Res. 2022. https://doi.org/10.1158/1078-0432.CCR-21-2517.CrossRef

69.

Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18:199–214. https://doi.org/10.1038/s41571-020-00455-z.CrossRef

70.

Xu Z, Chen X, Song L, Yuan F, Yan Y. Matrix remodeling-associated protein 8 as a novel indicator contributing to glioma immune response by regulating ferroptosis. Front Immunol. 2022;13:834595. https://doi.org/10.3389/fimmu.2022.834595.CrossRef

71.

Domingues P, Gonzalez-Tablas M, Otero A, Pascual D, Miranda D, Ruiz L, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1–15. https://doi.org/10.1016/j.bbi.2015.07.019.CrossRef

72.

Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol. 2021;12:721830. https://doi.org/10.3389/fimmu.2021.721830.CrossRef

73.

Zhang H, He J, Dai Z, Wang Z, Liang X, He F, et al. Pdia5 is correlated with immune infiltration and predicts poor prognosis in gliomas. Front Immunol. 2021;12:628966. https://doi.org/10.3389/fimmu.2021.628966.CrossRef

74.

Lu T, Zheng Y, Gong X, Lv Q, Chen J, Tu Z, et al. High expression of hyaluronan-mediated motility receptor predicts adverse outcomes: a potential therapeutic target for head and neck squamous cell carcinoma. Front Oncol. 2021;11:608842. https://doi.org/10.3389/fonc.2021.608842.CrossRef

75.

He Z, Mei L, Connell M, Maxwell CA. Hyaluronan mediated motility receptor (hmmr) encodes an evolutionarily conserved homeostasis, mitosis, and meiosis regulator rather than a hyaluronan receptor. Cells-Basel. 2020;9. https://doi.org/10.3390/cells9040819

76.

Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res. 2005;65:850–60.CrossRef

77.

Kouvidi K, Nikitovic D, Berdiaki A, Tzanakakis GN. Hyaluronan/rhamm interactions in mesenchymal tumor pathogenesis: role of growth factors. Adv Cancer Res. 2014;123:319–49. https://doi.org/10.1016/B978-0-12-800092-2.00012-5.CrossRef

78.

Uhlin U, Eklund H. Structure of ribonucleotide reductase protein r1. Nature. 1994;370:533–9. https://doi.org/10.1038/370533a0.CrossRef

79.

Pontarin G, Ferraro P, Bee L, Reichard P, Bianchi V. Mammalian ribonucleotide reductase subunit p53r2 is required for mitochondrial dna replication and dna repair in quiescent cells. Proc Natl Acad Sci USA. 2012;109:13302–7. https://doi.org/10.1073/pnas.1211289109.CrossRef

80.

Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, et al. Inhibiting rrm2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother. 2021;133:110996. https://doi.org/10.1016/j.biopha.2020.110996.CrossRef

81.

Aye Y, Li M, Long MJ, Weiss RS. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. 2015;34:2011–21. https://doi.org/10.1038/onc.2014.155.CrossRef

82.

Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of rrm2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13:3518–35. https://doi.org/10.18632/aging.202292.CrossRef

83.

Gandhi M, Gross M, Holler JM, Coggins SA, Patil N, Leupold JH, et al. The lncrna lincnmr regulates nucleotide metabolism via a ybx1 - rrm2 axis in cancer. Nat Commun. 2020;11:3214. https://doi.org/10.1038/s41467-020-17007-9.CrossRef

84.

Xie Y, Xue C, Guo S, Yang L. Microrna-520a suppresses pathogenesis and progression of non-small-cell lung cancer through targeting the rrm2/wnt axis. Anal Cell Pathol (Amst). 2021;2021:9652420. https://doi.org/10.1155/2021/9652420.CrossRef

85.

Li C, Zheng J, Chen S, Huang B, Li G, Feng Z, et al. Rrm2 promotes the progression of human glioblastoma. J Cell Physiol. 2018;233:6759–67. https://doi.org/10.1002/jcp.26529.CrossRef

86.

Rasmussen RD, Gajjar MK, Tuckova L, Jensen KE, Maya-Mendoza A, Holst CB, et al. Author correction: brca1-regulated rrm2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun. 2018;9:5396. https://doi.org/10.1038/s41467-018-07892-6.CrossRef

87.

Hill M, Tran N. Mirna interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021;14. https://doi.org/10.1242/dmm.047662

88.

Ali SZ, Langden S, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of microrna expression in cancer. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21051723

89.

Yang HD, Kim HS, Kim SY, Na MJ, Yang G, Eun JW, et al. Hdac6 suppresses let-7i-5p to elicit tsp1/cd47-mediated anti-tumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology. 2019;70:1262–79. https://doi.org/10.1002/hep.30657.CrossRef

90.

Liu Y, Hu X, Hu L, Xu C, Liang X. Let-7i-5p enhances cell proliferation, migration and invasion of ccrcc by targeting habp4. Bmc Urol. 2021;21:49. https://doi.org/10.1186/s12894-021-00820-9.CrossRef

91.

Sun X, Xue H, Xiong Y, Yu R, Gao X, Qian M, et al. Gale promotes the proliferation and migration of glioblastoma cells and is regulated by mir-let-7i-5p. Cancer Manag Res. 2019;11:10539–54. https://doi.org/10.2147/CMAR.S221585.CrossRef

92.

Georgiadou D, Boussata S, Keijser R, Janssen D, Afink GB, van Dijk M. Knockdown of splicing complex protein pcbp2 reduces extravillous trophoblast differentiation through transcript switching. Front Cell Dev Biol. 2021;9:671806. https://doi.org/10.3389/fcell.2021.671806.CrossRef

93.

van Dijk M, Visser A, Buabeng KM, Poutsma A, van der Schors RC, Oudejans CB. Mutations within the linc-hellp non-coding rna differentially bind ribosomal and rna splicing complexes and negatively affect trophoblast differentiation. Hum Mol Genet. 2015;24:5475–85. https://doi.org/10.1093/hmg/ddv274.CrossRef

Title: HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas
Authors: Huaxin Zhu
Jiacong Tan
Xinyi Pan
Hengyang Ouyang
Zhixiong Zhang
Meihua Li
Yeyu Zhao
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Glioma
Glioma
Glioma
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10596-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

Effect of genetic liability to migraine and its subtypes on breast cancer: a mendelian randomization study

A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis

Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China

Comparison of the effectiveness of lauromacrogol injection for ablation and microwave ablation in the treatment of predominantly cystic thyroid nodules: a multicentre study

Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer